Mark Finch, MD
Nuclear Cardiology · Cherry Hill, NJNPI 1336116995
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (42.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Boston Scientific at 59.1% of the total. Reporting peaked in 2023 at $9,499 and has fallen 51.7% since, to $4,587 in 2025. Among nuclear cardiology clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 465 payments — averaging $60.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$17K
- Heartflow, Inc.$5K
- Pfizer$1K
- GE HealthCare$1K
- Amgen$895
- Johnson & Johnson$776
- plus $3K from 23 others
Across 17 payments — averaging $3022.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Cleerly, Inc.$51K
What the payments were for
- Speaking & faculty fees$12,00043%
- Travel & lodging$4,07015%
- Food & beverage$11,93643%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 73 | $16,542 |
| Heartflow, Inc. | 47 | $4,891 |
| Pfizer | 80 | $1,171 |
| GE HealthCare | 2 | $1,111 |
| Amgen | 63 | $895 |
| Johnson & Johnson | 40 | $776 |
| E.r. Squibb & Sons, L.L.C. | 27 | $320 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 20 | $292 |
| Novartis | 19 | $222 |
| Edwards Lifesciences | 2 | $215 |
| Boehringer Ingelheim | 12 | $171 |
| Sanofi-aventis U.S. LLC | 15 | $158 |
| Amarin Pharma, Inc. | 12 | $156 |
| Alnylam Pharmaceuticals Inc. | 5 | $139 |
| Merck | 9 | $131 |
| Abiomed | 1 | $128 |
| Philips North America LLC | 7 | $120 |
| Atricure, Inc. | 2 | $105 |
| Esperion Therapeutics, Inc. | 5 | $101 |
| Regeneron Healthcare Solutions, Inc. | 7 | $95 |
| AstraZeneca | 6 | $81 |
| Kowa Pharmaceuticals America, Inc. | 3 | $36 |
| Kestra Medical Technology Services, Inc. | 2 | $35 |
| Medtronic | 1 | $31 |
| Avinger Inc. | 1 | $24 |
| Scpharmaceuticals Inc. | 1 | $20 |
| Actelion Pharmaceuticals US, Inc. | 1 | $16 |
| Impulse Dynamics (USA) Inc. | 1 | $12 |
| Gilead | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WATCHMAN Access System$13,830
- FFRct$4,184
- WATCHMAN FLX$789
- Watchman$465
- XARELTO$247
- ELIQUIS$239
- EVOQUE$196
- EMBLEM$139
How this compares
$28,006 in reported general payments places this provider in the 90th percentile of 34 nuclear cardiology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 313 | $355,435 |
| EntrestoSacubitril/Valsartan | 139 | $187,046 |
| XareltoRivaroxaban | 146 | $179,918 |
| Repatha SureclickEvolocumab | 75 | $82,055 |
| Praluent PenAlirocumab | 44 | $30,552 |
| Ezetimibe | 216 | $5,806 |
| Metoprolol Succinate | 349 | $5,431 |
| Rosuvastatin Calcium | 317 | $4,616 |
| Atorvastatin Calcium | 408 | $4,410 |
| Candesartan Cilexetil | 27 | $3,803 |
| Valsartan | 116 | $3,052 |
| Carvedilol | 213 | $2,712 |
| Amlodipine Besylate | 365 | $2,668 |
| Omega-3 Acid Ethyl Esters | 17 | $2,424 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 58 | $2,300 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $1,171 | $355,435313 claims |
| NovartisEntresto | $222 | $187,046139 claims |
| Johnson & JohnsonXarelto | $776 | $179,918146 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 34 nuclear cardiology providers in New Jersey.
Other nuclear cardiology in Cherry Hill
- Nasser ChaudhryCherry Hill$11K
- Nicole KelbonCherry Hill$7K
- Kristofer HillegasCherry Hill$4K
- David LawrenceCherry Hill$3K
- Amee DhariaCherry Hill$3K
- Rozy DunhamCherry Hill$3K
- Brett SealoveEatontown$410K
- Madhav UpadhyayaTinton Falls$89K
- Hafeza ShaikhWillingboro$16K
- Ralph RussoMoorestown$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.